Medical Oncology

, 30:461 | Cite as

Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma

Original Paper

Abstract

It has been reported that the imbalance of T helper IL-17-producing cells (Th17 cells)/regulatory T cells (Tregs) was closely associated with advanced tumor growth and poor prognosis in lung cancer, but little is known about whether this imbalance is existed in the peripheral blood of patients with non-small cell lung cancer (NSCLC). Here, the percentage of Treg and Th17 cells, and the expression of transcription factors RORγt and FoxP3 were studied by flow cytometry, real-time PCR, and Western blotting, respectively. Levels of serum cytokines (IL-6, IL-17, IL-10, and TGF-β1) were analyzed by ELISA. The results showed that there was an increase in the percentage of Tregs, the mRNA and protein expression of FoxP3, the level of Treg-related cytokines in patients with NSCLC while compared to that in healthy patients. Moreover, the percentage of Th17 cells, RORγt mRNA, and protein expression were decreased in peripheral blood of NSCLC patients. In addition, Th17/Treg ratio was decreased in lung cancer patients when compared with healthy patients and Th17/Treg ratio was negatively correlated with the stages. Our results indicate that the Th17/Treg balance is abnormal in peripheral blood, which may be important in the development of NSCLC.

Keywords

Adenocarcinoma  Squamous cell carcinoma T regulatory cells Th17 cells Flow cytometry 

References

  1. 1.
    Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107(12):2866–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRefGoogle Scholar
  3. 3.
    Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2011;75(1):95–101.PubMedCrossRefGoogle Scholar
  4. 4.
    Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13(3):902–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29(42):5653–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 2008;58(3):875–87.PubMedCrossRefGoogle Scholar
  10. 10.
    Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A. Fazekas de St Groth B. Expression of interleukin(IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+ CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005;14(5):1269–73.PubMedGoogle Scholar
  12. 12.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Jacobs JFM, Nierkens S, Figdor CG, de Vries IJM, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol. 2012;13(1):E32–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee WC, Wu TJ, Chou HS, Yu MC, Hsu PY, Hsu HY, Wang CC. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma. Surgery. 2012;151(2):213–22.PubMedCrossRefGoogle Scholar
  15. 15.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766–72.PubMedGoogle Scholar
  16. 16.
    Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168(9):4272–6.PubMedGoogle Scholar
  17. 17.
    Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK, Das SN. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol. 2012;35(5):335–43.CrossRefGoogle Scholar
  18. 18.
    Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–90.PubMedGoogle Scholar
  19. 19.
    Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Koyama K, Kagamu H, Miura S, Hiura T, Miyabayashi T, Itoh R, Kuriyama H, Tanaka H, Tanaka J, Yoshizawa H, Nakata K, Gejyo F. Reciprocal CD4+ T-cell balance of effector CD62L low CD4+ and CD62L high CD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008;14(21):6770–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, Bailer R, Graham BS, Roederer M, Koup RA. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med. 2007;204(6):1405–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31(5):787–98.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Lei Zhao
    • 1
    • 2
  • Jin Yang
    • 2
  • Hui-Ping Wang
    • 3
  • Rong-Yu Liu
    • 1
  1. 1.Department of Pulmonary, Anhui Geriatric InstituteThe First Affiliated Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China
  2. 2.Department of Respiratory MedicineThe Second Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China
  3. 3.Department of Haematology LaboratoryThe Second Hospital of Anhui Medical UniversityHefeiPeople’s Republic of China

Personalised recommendations